Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

REMS For Opioids Still Has A Long Road Ahead; Advisory Committee Is Likely

Executive Summary

A finalized Risk Evaluation and Mitigation Strategy for opioids is a long way off - possibly more than a year - and FDA expects additional stakeholder and industry meetings, as well as a multidisciplinary advisory committee to take place before a program is set in stone

You may also be interested in...



As Opioid REMS Meeting Nears, FDA Notes Worry About Shifting Use To Different Class

In NEJM editorial, FDA's Woodcock suggests "unintended consequences" of any risk management plan for the pain products.

FDA Warns King Of Warning Letter: Firm Got Head Start On Fixing Embeda Ads

FDA's early intervention regarding misleading advertisements for King's morphine product Embeda gave the company a head start on reviewing its promotional pieces, but it did not mean the company could escape from the official warning letter

FDA Warns King Of Warning Letter: Firm Got Head Start On Fixing Embeda Ads

FDA's early intervention regarding misleading advertisements for King's morphine product Embeda gave the company a head start on reviewing its promotional pieces, but it did not mean the company could escape from the official warning letter

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS051150

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel